Skip to content

Clinical trials

Observational Diabetes Mellitus, Type 2 trials in the United States

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Diabetes Mellitus, Type 2 Phase: Observational Country / region: United States Clear all

329 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20004
20013
20035
20044
20055
20066
200720
200815
200912
201013
201117
201222
201310
201418
201511
201614
201717
201810
201913
20208
202118
202217
202317
202417
202512
202613

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed228
Recruiting28
Unknown status22
Terminated17
Active, not recruiting14
Withdrawn13
Enrolling by invitation6
Suspended1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Brigham and Women's Hospital22
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)14
AstraZeneca12
VeraLight, Inc.9
Bayer8
HealthPartners Institute8
University of Colorado, Denver8
Boehringer Ingelheim7
Mayo Clinic7
Novo Nordisk A/S6

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Diabetes Mellitus, Type 2329
Diabetes Mellitus67
Obesity52
Diabetes Mellitus, Type 140
Insulin Resistance37
Cardiovascular Diseases25
Renal Insufficiency, Chronic14
Hypertension13
Prediabetic State12
Overweight11

Trials

Showing 1 to 25 of 329. Each trial links to its page on Pharma Observatory.

229 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.